Polymyalgia Rheumatica (PMR) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Polymyalgia Rheumatica (PMR) – Drugs In Development, 2024 report and make more profitable business decisions.
Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in white adults over 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP).
The Polymyalgia Rheumatica (PMR) drugs in development market research report provide comprehensive information on the therapeutics under development for Polymyalgia Rheumatica (PMR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polymyalgia Rheumatica (PMR) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Polymyalgia Rheumatica (PMR) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Polymyalgia Rheumatica (PMR) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Polymyalgia Rheumatica (PMR) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Polymyalgia Rheumatica (PMR) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Biogen IncBristol-Myers Squibb Co
Eli Lilly and Co
ellennbe GmbH
F. Hoffmann-La Roche Ltd
Novartis AG
Sparrow Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Polymyalgia Rheumatica (PMR) reports